CN108409727A - A kind of inhibitors of fatty amide hydrolase and preparation method thereof - Google Patents
A kind of inhibitors of fatty amide hydrolase and preparation method thereof Download PDFInfo
- Publication number
- CN108409727A CN108409727A CN201810457983.XA CN201810457983A CN108409727A CN 108409727 A CN108409727 A CN 108409727A CN 201810457983 A CN201810457983 A CN 201810457983A CN 108409727 A CN108409727 A CN 108409727A
- Authority
- CN
- China
- Prior art keywords
- amide hydrolase
- fatty amide
- inhibitors
- mmol
- faah
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 208000002193 Pain Diseases 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 10
- 108700022737 rat Fat1 Proteins 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 abstract description 4
- 238000012827 research and development Methods 0.000 abstract description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
- 102000004157 Hydrolases Human genes 0.000 description 20
- 108090000604 Hydrolases Proteins 0.000 description 20
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 101000937693 Homo sapiens Fatty acid 2-hydroxylase Proteins 0.000 description 17
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 description 17
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- OMZSGWSJDCOLKM-UHFFFAOYSA-N copper(II) sulfide Chemical compound [S-2].[Cu+2] OMZSGWSJDCOLKM-UHFFFAOYSA-N 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- HXDOZKJGKXYMEW-UHFFFAOYSA-N 4-ethylphenol Chemical compound CCC1=CC=C(O)C=C1 HXDOZKJGKXYMEW-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- HVBCJKTZKQWQAU-UHFFFAOYSA-N 1-bromopyrrole Chemical class BrN1C=CC=C1 HVBCJKTZKQWQAU-UHFFFAOYSA-N 0.000 description 3
- IQPBUDMTXHWSHB-ZKWNWVNESA-N AMC Arachidonoyl Amide Chemical compound CC1=CC(=O)OC2=CC(NC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC)=CC=C21 IQPBUDMTXHWSHB-ZKWNWVNESA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- -1 ethyl phenoxy Chemical group 0.000 description 3
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical class ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000002190 fatty acyls Chemical group 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MENAYYMPBRSAAE-AWEZNQCLSA-N 3-[[5-[[(2s)-1-carboxy-3-oxopropan-2-yl]carbamoyl]pyridin-2-yl]methylsulfamoyl]benzoic acid Chemical compound N1=CC(C(=O)N[C@@H](CC(=O)O)C=O)=CC=C1CNS(=O)(=O)C1=CC=CC(C(O)=O)=C1 MENAYYMPBRSAAE-AWEZNQCLSA-N 0.000 description 1
- SJTBRFHBXDZMPS-UHFFFAOYSA-N 3-fluorophenol Chemical class OC1=CC=CC(F)=C1 SJTBRFHBXDZMPS-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 102000004092 Amidohydrolases Human genes 0.000 description 1
- 108090000531 Amidohydrolases Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010074124 Escherichia coli Proteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 229940124036 Hydrolase inhibitor Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101710094902 Legumin Proteins 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical class ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000002621 endocannabinoid Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003940 fatty acid amidase inhibitor Substances 0.000 description 1
- 150000002193 fatty amides Chemical class 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001905 globus pallidus Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 239000004093 hydrolase inhibitor Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000005220 pharmaceutical analysis Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of inhibitors of fatty amide hydrolase and preparation method thereof, structural formula isWherein, X is selected from C；R1Selected from H；R2Selected from H；R3Selected from H.Compound by test has inhibitory activity well, hFAAH IC for people and rat fat hydroamidase50（nM）For 28, rFAAH IC50（nM）It is 110.Illustrate the follow-up research and development that the compound of the present invention can be as inhibitors of fatty amide hydrolase for the preparation of related drugs.
Description
It is on October 25th, 2017 that the application, which is the applying date, entitled " a kind of application No. is 2017110102607
The divisional application of the patent of inhibitors of fatty amide hydrolase and preparation method thereof ".
Technical field
The present invention relates to a kind of inhibitors of fatty amide hydrolase and preparation method thereof, belong to pharmaceutical chemistry, Pharmaceutical Analysis,
The combination in the fields such as pharmaceutical preparation and pharmaceutical activity test.
Background technology
Fatty amide hydrolase（Fatty acid amide hydrolase, FAAH）It is a kind of inner membrance amide FAAH signals
Family protein enzyme, it is many biologically active fatty acid amides in organism（Fatty acid amide）Messenger molecule
Major catalytic hydrolyzes metabolic enzyme.The fatty amide hydrolase being originally found is found in liver by Schmid and his colleagues
N- acyl ethanol amines amidohydrolase.This hydrolase can be by N- acyl ethanol amines（NAE）Hydrolysis generate aliphatic acid and
Ethanol amine.1996, Cravatt etc. came out this enzyme clone, is named as fatty amide hydrolase（FAAH）.In human body
Fatty amide hydrolase enzyme contains 597 amino acid, molecular weight 63KDa.Fatty amide hydrolase is mainly distributed on microsome
And on the film of mitochondria.FAAH is appeared in Various Tissues, including head, intestines, liver, testis, uterus, kidney, eyes, spleen and lung etc..
In the brain, FAAH is also different in not same district expression degree, most strong in globus pallidus region and hippocampus activity, and in brains
Activity is worst；In immune system, FAAH activity is by lymphocyte and Expression of Macrophages.FAAH is as endocannabinoids system
The forming member of system plays an important role to the termination of cannboid signal, be the nervous system disease, inflammation, metabolic disease and
The potential target spot for the treatment of cardiovascular disease.
The catalytic center of FAAH is the catalytic triads that Ser241, Ser217 and Lysl42 are constituted, and contains multiple channels
And chamber, including film access channel（Membrane access channel, MAC）, by active site and electrodes method film surface phase
Even；Cytoplasm accesses channel, and hydroaropic substance is allowed to exit activated centre（cytosolic access channel）；In conjunction with fat
The hydrophobic region of fat acid chain is known as fatty acid chain combined area（Acyl chain-binding pocket, ABP）, eutectic is adjusted
The fatty acid chain of body inhibitor.
Although not there is the listing of FAAH inhibitor also at present, has multiple drugs and surveyed in clinical and preclinical bioactivity
The examination stage.According to Thomson Reuters Cortellis statistics of database, there are multiple drugs to be in conceptual phase at present.
Invention content
One of the objects of the present invention is to provide a kind of inhibitors of fatty amide hydrolase, structural formula is
Wherein, X is selected from C or N；R1Selected from H or C；R2Selected from H, C or F；R3Selected from H, C, F or CH2CH3。
Further, salt or its solvated compounds.
Another object of the present invention is to provide a kind of synthetic routes of inhibitors of fatty amide hydrolase：
。
Another object of the present invention is to provide a kind of inhibitors of fatty amide hydrolase for treating, preventing or assisting to control
Treat the application in adjusting fatty amide hydrolase relevant disease in mammal and people, the disease such as pain, including it is acute
And it is chronic, the pain as caused by postoperative pain, chronic pain, pain caused by cancer, cancer chemotherapy, neuralgia, nociception pain, inflammatory
Bitterly, backache, the pain caused by the disease such as following various sources：Diabetic neuropathy including human immunodeficiency virus
Thermophilic nervous system type viral disease, pain such as post herpetic neuralgia caused by herpes zoster；Polyneuropathy, neurotoxicity, machinery
Neurotrosis, complication of wrist, amynologic mechanism such as multiple sclerosis.
Further, application of the inhibitors of fatty amide hydrolase in the drug for the treatment of pain.
Another object of the present invention is to a kind of compositions, including fatty amide hydrolase described in claim 1 to inhibit
Agent and pharmaceutically acceptable auxiliary material.
Further, the inhibitors of fatty amide hydrolase described in the composition is as sole active agent.
Obviously, the above according to the present invention is not departing from this hair according to the ordinary technical knowledge and means of this field
Under the premise of bright above-mentioned basic fundamental thought, the modification, replacement or change of other diversified forms can also be made.
Specific implementation mode
Intermediate one：The synthesis of the bromo- 1H- pyrroles -2- formyl chlorides of 4-
The bromo- 1H- pyrroles -2- formamides of compound 4- (10 mmol) are dissolved in 30 milliliters of dichloromethane, 5 milliliters are added thereto
Then DMF is added dropwise 3 grams of thionyl chlorides, is heated to flowing back, stir 5 hours, and decompression steams solvent, and 20 milliliters of first are added thereto
Benzene, decompression steam toluene and simultaneously take away remaining thionyl chloride, and products obtained therefrom is directly used in react in next step.1H-NMR
(400 MHz, CDCl3) δ: 7.17-7.22(m, 2H), 8.97(s, 1H)。
Intermediate two：The synthesis of the bromo- N- of 4- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -1H- pyrroles's -2- formamides
The bromo- 1H- pyrroles -2- acyl chlorides of the crude product 4- of previous step is dissolved in 40 milliliters of dichloromethane solutions, 10 millis are added thereto
Triethylamine is risen, control temperature is less than 10 DEG C, is added dropwise to 3- methyl-1s into system, and the two of 2,4- thiadiazoles -5- amine (12 mmol)
Chloromethanes solution, restore room temperature after being added dropwise, then stirring at normal temperature 10 hours is washed with 50 milliliter 5% of aqueous sodium carbonate
Wash reaction system, organic phase anhydrous Na2SO4Dry, after solvent evaporated, obtained solid flash column chromatography separation obtains 2.45
G light yellow solids, two step gross production rates 85%.1H-NMR (400 MHz, CDCl3) δ: 2.18(s, 3H), 6.78(d, 1H),
7.16(d, 1H), 8.83(s, 1H)。
Embodiment 1：The synthesis of N- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -4- phenoxy group -1H- pyrrole radicals -2- formamides
The bromo- N- of 4- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -1H- pyrroles -2- formamides (10 mmol) are dissolved in 30 ml toluene
In, copper sulfide (1 mmol) and cesium carbonate (12 mmol) are added thereto, stirs half an hour, phenol (12 is added thereto
Mmol), reacted 10 hours after system is heated to 100 DEG C.Then it is cooled to room temperature, is filtered, solvent evaporated, flash column chromatography point
From it is solid that 2.3 g off-white colors N- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -4- phenoxy group -1H- pyrrole radicals -2- formamides can be obtained
Body, yield 77%.1H-NMR (400 MHz, CDCl3) δ: 2.18(s, 3H), 6.23(d, 1H), 6.45(d,1H),
6.91-7.02(m, 3H), 7.29(m, 2H), 8.64(s, 1H).13C-NMR (75 MHz, CDCl3) δ:17.71,
108.26, 119.9, 120.66, 121.66, 124.89, 129.81, 143.43, 153.96, 162.46,
167.63, 173.89.LC-MS(ESI, pos, ion) m/z: 301[M+1]。
Embodiment 2：N- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -4- (2- pyridines oxygroup) -1H- pyrrole radicals -2- formamides
Synthesis
The bromo- N- of 4- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -1H- pyrroles -2- formamides (10 mmol) are dissolved in 30 ml toluene
In, copper sulfide (1 mmol) and cesium carbonate (12 mmol) are added thereto, stirs half an hour, 2 hydroxy pyrimidine is added thereto
(12 mmol), system are reacted 10 hours after being heated to 100 DEG C.Then it is cooled to room temperature, is filtered, solvent evaporated, flash column chromatography
Separation, can obtain the faint yellow N- of 2.4 g (3- methyl-1s, 2,4- thiadiazolyl groups -5) -4- (2- pyridines oxygroup) -1H- pyrrole radicals -2- first
Amide solid, yield 80%.1H-NMR (400 MHz, CDCl3) δ: 2.15(s, 3H), 6.00(d, 1H), 6.36-
6.38(m, 2H), 6.54(dd, 1H), 7.21(dd, 1H), 7.58(dt, 1H), 8.59(s, 1H).13C-NMR (75
MHz, CDCl3) δ: 17.71, 108.26, 116.02, 118.61, 120.82, 121.66, 137.45, 143.09,
148.62, 162.36, 162.46, 167.63, 173.89.LC-MS(ESI, pos, ion) m/z: 302[M+1]。
Embodiment 3：N- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -4- (3- fluorophenoxies) -1H- pyrrole radicals -2- formamides
Synthesis
The bromo- N- of 4- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -1H- pyrroles -2- formamides (10 mmol) are dissolved in 30 ml toluene
In, copper sulfide (1 mmol) and cesium carbonate (12 mmol) are added thereto, stirs half an hour, 3- fluorophenols (12 are added thereto
Mmol), reacted 10 hours after system is heated to 100 DEG C.Then it is cooled to room temperature, is filtered, solvent evaporated, flash column chromatography point
From the faint yellow N- of 2.6 g (3- methyl-1s, 2,4- thiadiazolyl groups -5) -4- (3- fluorophenoxies) -1H- pyrrole radicals -2- formyls can be obtained
Amine solid, yield 84%.1H-NMR (400 MHz, CDCl3) δ: 2.19(s, 3H), 6.07(d, 1H), 6.44(d,
1H), 6.68(m, 1H), 7.27(m, 1H), 7.46(m, 1H), 7.60(m, 1H), 8.85(s, 1H).13C-NMR
(75 MHz, CDCl3) δ: 17.71, 108.26, 108.49, 111.04, 116.13, 120.66, 121.66,
131.17, 143.43, 155.32, 162.46, 163.83, 167.63, 173.89.LC-MS(ESI, pos, ion)
m/z:319[M+1]。
Embodiment 4：N- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -4- (to ethyl phenoxy group) -1H- pyrrole radicals -2- formyls
The synthesis of amine
The bromo- N- of 4- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -1H- pyrroles -2- formamides (10 mmol) are dissolved in 30 ml toluene
In, copper sulfide (1 mmol) and cesium carbonate (12 mmol) are added thereto, stirs half an hour, paraethyl phenol is added thereto
(12 mmol), system are reacted 10 hours after being heated to 100 DEG C.Then it is cooled to room temperature, is filtered, solvent evaporated, flash column chromatography
Separation, can obtain 2.8 g N- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -4- (to ethyl phenoxy group) -1H- pyrrole radicals -2- formyls
Amine solid, yield 85%.1H-NMR (400 MHz, CDCl3) δ: 1.18(t, 3H), 2.18(s, 3H), 2.72(q.
2H). 6.07(d, 1H), 6.41(d, 1H), 7.01(m, 2H), 7.14(m, 2H), 8.62(s, 1H).13C-NMR
(75 MHz, CDCl3) δ: 13.19, 17.71, 27.82, 108.26, 120.66, 120.82, 121.66,
127.78, 139.92, 143.43, 152.41, 162.46, 167.63, 173.89.LC-MS(ESI, pos, ion)
m/z: 329[M+1]。
Embodiment 5：N- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -4- (2,3 dimethyl phenoxy) -1H- pyrrole radicals -2-
The synthesis of formamide
The bromo- N- of 4- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -1H- pyrroles -2- formamides (10 mmol) are dissolved in 30 ml toluene
In, copper sulfide (1 mmol) and cesium carbonate (12 mmol) are added thereto, stirs half an hour, paraethyl phenol is added thereto
(12 mmol), system are reacted 10 hours after being heated to 100 DEG C.Then it is cooled to room temperature, is filtered, solvent evaporated, flash column chromatography
Separation, can obtain 2.7 g yellow N- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -4- (2,3 dimethyl phenoxy) -1H- pyrrole radicals -
2- formamide solids, yield 82%.1H-NMR (400 MHz, CDCl3) δ: 2.08(s, 3H), 2.18(s, 3H), 2.29
(s, 3H), 6.08(d, 1H), 6.35(d, 1H), 6.79-6.89(m, 3H), 8.68(s, 1H). 13C-NMR (75
MHz, CDCl3) δ: 13.38, 17.71, 19.79, 108.26, 117.32, 119.41, 121.66, 125.25,
125.31, 127.98, 137.11, 143.35, 154.08, 162.46, 167.63, 173.89.LC-MS(ESI,
pos, ion) m/z: 329[M+1]。
Test example 1：People and rat fat amide hydrolysis enzyme inhibition activity
The compounds of this invention is to people and rat fat hydroamidase（FAAH）Inhibitory activity, test method are same
CN103958473B, unless otherwise stated, all reagents are purchased from Sigma.It is summarized as follows：
Material and reagent：
People for analysis and rat fat hydroamidase（FAAH）Gene is by Patricelli etc.
（Biochemistry.1998,37（43）, 15177-87）Description.The fatty amide hydrolase that membrane-spanning domain is deleted（FAAH）Gene
It is cloned into pET15b（Novagen, #69661）（People FAAH）/pET28a（Novagen, #69864-3）（Rat FAAH genes）Matter
In grain and in Escherichia coli（Ecoli）It is expressed in BL21DE3.PGR07 plasmids（Takara Bio Inc, Japan）In companion's egg
White groEL-groES and fatty amide hydrolase（FAAH）Coexpression, so as to improve expression in escherichia coli protein it is molten
Xie Du.Such as Mileni（Proc NatlAcad Sci USA.2008,105（35）, 12820-4）In it is recorded, to express simultaneously
Enrichment protein.In short, using arabinose at room temperature（2mM）With isopropyl ss-D-1- thiogalactosides（IPTG）（1mM）
Induce LB culture mediums（Luria Broth）（2L）In bacterial cultures 20h.Culture is centrifuged into 10min at 1200 × g,
And by cell mass（cell pellet）It is resuspended in 100mL NaPi containing 20mM（pH7.4）, 100mM NaCl, nuclease（500u）、
Aprotinin（1μg/mL）And leupeptin（1μg/mL）Buffer solution in.Pass through sonic method（Amp 20%, pulse 15s × 15, ice
On）Lytic cell, and remove cell fragment by centrifuging 20min under 5000 × g.Suspension through exceed the speed limit under 100,000 × g from
Heart 1h enrichments, and cell mass is resuspended in 16mL NaPi containing 20mM（pH7.8）, 500mM NaCl, 1% triton x-100 it is slow
In fliud flushing.The cell extract of suspension carries out ultracentrifugation 1h under 100,000 × g, and by the suspension of enrichment for external
Analysis.All proteins extraction step carries out on ice or at 4 DEG C.
Analyzed in vitro：
The bioactivity of compound is evaluated using fluorescence-based analysis, to which quantitative arachidonic base 7- amino, 4 methyl are fragrant
Legumin amide（AAMCA）, fatty amide hydrolase（FAAH）Fluorogenic substrate hydrolysis（Anal Biochem.2005、343
(1)：143-51）.In 96 hole black polystyrene plates（Greiner Bio-one, Germany）In divided with 200 μ L volumes
Analysis.Each reaction is by containing 50mM HEPES, 1mM EDTA and 0.1%BSA（PH7.4）Analysis buffer in people's fatty acyl aqueous amine
Solve enzyme（FAAH）Albumen and 10 μM of AAMCA are constituted.With the inhibitor of 2 μ L various concentrations in DMSO（The final concentration 1% of DMSO）
Oscillation while incubation reaction 1min and in 50min monitor kinetics model in fluorescence increase.In excitation wavelength 355nm
Down and under 460nm transmittings, Flexstation III microplate reader is used（Molecular Devices, Sunnyvale, CA）It surveys
Measure the increase of fluorescence.The reaction rate of function used as inhibitor concentration measures the IC of inhibitor50.Use Graph
PadPrism（Graph Pad Software Inc., San Diego, CA）Analyze data.Rat fat acyl is utilized as described above
Amine hydrolase（FAAH）Albumen and 10 μM of AAMCA substrates evaluate compound to rat fat hydroamidase（FAAH）Activity.
, 1 the compounds of this invention of table is to people and rat FAAH inhibitory activity.
| hFAAH IC50（nM） | rFAAH IC50（nM） | |
| Embodiment 1 | 28 | 110 |
| Embodiment 2 | 6 | 127 |
| Embodiment 3 | 2 | 73 |
| Embodiment 4 | 17 | 82 |
| Embodiment 5 | 22 | 86 |
| OL-135 | 10 | 79 |
Inhibit to live well the result shows that the compound by test has people and rat fat hydroamidase
Property, IC50Value is within the scope of 2nM to 127nM, the IC of embodiment 350Value is 2nM.Positive control OL-135 is to people and rat fat
The inhibitory activity IC of fat hydroamidase50Value is respectively 10nM and 79nM.Illustrate that the compound of the present invention can be used as fatty acyl
Follow-up research and development of the amine hydrolase inhibitor for the preparation of related drugs.
Claims (6)
1. a kind of inhibitors of fatty amide hydrolase, structural formula are
Wherein, X is selected from C；R1Selected from H；R2Selected from H；R3Selected from H.
2. the synthetic route of inhibitors of fatty amide hydrolase as described in claim 1 is
。
3. inhibitors of fatty amide hydrolase as described in claim 1 for treat, prevent or auxiliary treatment mammal and
Application in people in adjusting fatty amide hydrolase relevant disease.
4. application of the inhibitors of fatty amide hydrolase as described in claim 1 in the drug for the treatment of pain.
5. a kind of composition, which is characterized in that including inhibitors of fatty amide hydrolase described in claim 1 and pharmaceutically may be used
The auxiliary material of receiving.
6. composition as claimed in claim 4, which is characterized in that inhibitors of fatty amide hydrolase described in claim 1
As sole active agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810457983.XA CN108409727A (en) | 2017-10-25 | 2017-10-25 | A kind of inhibitors of fatty amide hydrolase and preparation method thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711010260.7A CN107602550B (en) | 2017-10-25 | 2017-10-25 | A kind of fatty acid amidohydrolase inhibitor and preparation method thereof |
| CN201810457983.XA CN108409727A (en) | 2017-10-25 | 2017-10-25 | A kind of inhibitors of fatty amide hydrolase and preparation method thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711010260.7A Division CN107602550B (en) | 2017-10-25 | 2017-10-25 | A kind of fatty acid amidohydrolase inhibitor and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108409727A true CN108409727A (en) | 2018-08-17 |
Family
ID=61080386
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810457983.XA Withdrawn CN108409727A (en) | 2017-10-25 | 2017-10-25 | A kind of inhibitors of fatty amide hydrolase and preparation method thereof |
| CN201711010260.7A Active CN107602550B (en) | 2017-10-25 | 2017-10-25 | A kind of fatty acid amidohydrolase inhibitor and preparation method thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711010260.7A Active CN107602550B (en) | 2017-10-25 | 2017-10-25 | A kind of fatty acid amidohydrolase inhibitor and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN108409727A (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2065369A4 (en) * | 2006-08-23 | 2011-12-28 | Astellas Pharma Inc | Urea compound or salt thereof |
| JO3598B1 (en) * | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | Boronic acids and esters as inhibitors of fatty acid amide hydrolase |
| TWI434842B (en) * | 2008-07-14 | 2014-04-21 | Astellas Pharma Inc | Azole compounds |
| WO2011072207A1 (en) * | 2009-12-11 | 2011-06-16 | E. I. Du Pont De Nemours And Company | Azocyclic inhibitors of fatty acid amide hydrolase |
| WO2015200682A1 (en) * | 2014-06-25 | 2015-12-30 | Vanderbilt University | Substituted 4-alkoxypicolinamide analogs ds mglur5 negative allosteric modulators |
-
2017
- 2017-10-25 CN CN201810457983.XA patent/CN108409727A/en not_active Withdrawn
- 2017-10-25 CN CN201711010260.7A patent/CN107602550B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107602550A (en) | 2018-01-19 |
| CN107602550B (en) | 2018-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Heltweg et al. | Subtype selective substrates for histone deacetylases | |
| US10059657B2 (en) | Class-and isoform-specific HDAC inhibitors and uses thereof | |
| Suzuki et al. | Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors | |
| Luo et al. | Role of the multifunctional DNA repair and redox signaling protein Ape1/Ref-1 in cancer and endothelial cells: small-molecule inhibition of the redox function of Ape1 | |
| Martínez et al. | Multitarget anticancer agents based on histone deacetylase and protein kinase CK2 inhibitors | |
| Zhou et al. | Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings | |
| Mai et al. | Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors | |
| Suzuki et al. | Novel histone deacetylase inhibitors: design, synthesis, enzyme inhibition, and binding mode study of SAHA-based non-hydroxamates | |
| Afroz et al. | Synthesis, characterization and biological screening of sulfonamides derived form 2-phenylethylamine. | |
| Huan et al. | Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity | |
| CN116897153A (en) | A triazole derivative and its preparation method and application | |
| Liu et al. | 1, 4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma | |
| WO2004046081A1 (en) | Beta-nitrostyrene compound and telomerase inhibitor having an anticancer activity | |
| Zhou et al. | Catecholic amides as potential selective phosphodiesterase 4D inhibitors: design, synthesis, pharmacological evaluation and structure–activity relationships | |
| Sun et al. | Design, synthesis, and antitumor activity evaluation of carbazole derivatives with potent HDAC inhibitory activity | |
| Rezaee et al. | Novel amide derivatives of 3-phenylglutaric acid as potent soluble epoxide hydrolase inhibitors | |
| CN108409727A (en) | A kind of inhibitors of fatty amide hydrolase and preparation method thereof | |
| Ji et al. | Conformationally restricted dipeptide amides as potent and selective neuronal nitric oxide synthase inhibitors | |
| CN113582864A (en) | PRMTI type methyltransferase inhibiting active compound, preparation and application thereof | |
| Ping et al. | Design, synthesis and antitumor activity evaluation of benzimidazole derivatives with potent HDAC inhibitory activity | |
| CN116768815B (en) | Isatoic anhydride compounds and preparation method and use thereof | |
| Lan et al. | Synthesis and evaluation of 6-methylcoumarin derivatives as potent and selective monoamine oxidase B inhibitors | |
| Litty et al. | Design, synthesis, and bioactivation of O-glycosylated prodrugs of the natural nitric oxide precursor N ω-Hydroxy-l-arginine | |
| CN118221610A (en) | A phenylthiazolamine PI4KIIIβ/HDAC dual-target inhibitor, preparation method, pharmaceutical composition and application thereof | |
| CN114685457B (en) | An enzalutamide photoaffinity probe and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180817 |